Lysosomal Zn2+ release triggers rapid, mitochondria-mediated, non-apoptotic cell death in metastatic melanoma

Cell Rep. 2021 Oct 19;37(3):109848. doi: 10.1016/j.celrep.2021.109848.

Abstract

During tumor progression, lysosome function is often maladaptively upregulated to match the high energy demand required for cancer cell hyper-proliferation and invasion. Here, we report that mucolipin TRP channel 1 (TRPML1), a lysosomal Ca2+ and Zn2+ release channel that regulates multiple aspects of lysosome function, is dramatically upregulated in metastatic melanoma cells compared with normal cells. TRPML-specific synthetic agonists (ML-SAs) are sufficient to induce rapid (within hours) lysosomal Zn2+-dependent necrotic cell death in metastatic melanoma cells while completely sparing normal cells. ML-SA-caused mitochondria swelling and dysfunction lead to cellular ATP depletion. While pharmacological inhibition or genetic silencing of TRPML1 in metastatic melanoma cells prevents such cell death, overexpression of TRPML1 in normal cells confers ML-SA vulnerability. In the melanoma mouse models, ML-SAs exhibit potent in vivo efficacy of suppressing tumor progression. Hence, targeting maladaptively upregulated lysosome machinery can selectively eradicate metastatic tumor cells in vitro and in vivo.

Keywords: ML-SAs; ML-SIs; TRPML1; Zn(2+); cell death; lysosome; metastatic melanoma; mitochondria; small molecule.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Video-Audio Media

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Death
  • Cell Line, Tumor
  • Female
  • Gene Expression Regulation, Neoplastic
  • HEK293 Cells
  • Humans
  • Lysosomes / drug effects*
  • Lysosomes / metabolism
  • Lysosomes / pathology
  • Melanocytes / drug effects*
  • Melanocytes / metabolism
  • Melanocytes / pathology
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / metabolism
  • Melanoma / secondary
  • Mice
  • Mice, Nude
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Signal Transduction
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Time Factors
  • Transient Receptor Potential Channels / agonists*
  • Transient Receptor Potential Channels / genetics
  • Transient Receptor Potential Channels / metabolism
  • Up-Regulation
  • Xenograft Model Antitumor Assays
  • Zinc / metabolism*

Substances

  • Antineoplastic Agents
  • MCOLN1 protein, human
  • Transient Receptor Potential Channels
  • Zinc